A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

Inclusion Criteria Patients must have: * HIV-positivity. * Diagnosed KS proven by biopsy. * NOTE: * Patients must not opt for immediate topical, systemic or radiation treatment. * At least 4 cutaneous lesions not treated within the previous 4 weeks. * Life expectancy \> 6 months. * Signed, informed consent from parent or legal guardian for those patients \< 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following conditions and symptoms are excluded: * Neoplastic disease (excluding KS) requiring systemic cytotoxic or radiation therapy or who have had these therapies within 1 month of baseline and have not completely recovered from the effects of these therapies. * Unstable or severe intercurrent medical conditions, including but not limited to, significant symptomatic visceral KS. * Clinically significant malabsorption syndrome. * Renal insufficiency. Patients with any of the following prior conditions are excluded: Significant Fever (\> 101 degrees F (38 degrees C) for \>= 7 days) and/or diarrhea (\> 6 loose stools/day for \>= 7 days) within one month of baseline. 1\. Immediate topical or systemic treatment for KS lesions. * Use of Retinoid class drugs, either topically or systemically, or beta-carotene compounds or Vitamin A doses of more than 15,000 IU (5,000 mcg) per day concurrently. Immediate radiation treatment. 1\. Treatment of KS lesions with intra-lesional chemotherapy within 4 weeks of entry. * History of \> 2 weeks of prior therapy with Indinavir or Ritonavir. * Use of Retinoid class drugs, either topically or systemically, or beta-carotene compounds or Vitamin A doses of more than 15,000 IU (5,000 mcg) per day within 4 weeks of entry. Treatment of KS lesions with radiation within 4 weeks of entry. Active substance abusers; urine drug tests may be performed if drug abuse is suspected.